Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank75
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Latest
-7.52%
↑ 79% vs avg
Percentile
P75
Within normal range
Streak
1 yr
Consecutive growthAccelerating
Average
-36.22%
Historical baseline
PeriodValue
2025-7.52%
2024-57.55%
2023-24.66%
2022-49.20%
202129.11%
2020-15.35%
2019-104.06%
2018-30.79%
2017-30.65%
2016-71.55%